// App-Quantinova.ai

: MRD-Negativity As a Potential Surrogate Endpoint after Frontline DLBCL Therapy: Pooled Analysis of Trials & Implications for Clinical Trial Design

Researchers

Presenter

  • Mark Roschewski

Principal Investigators

  • David M. Kurtz

  • Jason Westin

  • Ryan C. Lynch

  • Charles Macaulay

  • Christian Kuffer

  • Gregory J. Hogan

  • Sandra Close

  • Jacob J. Chabon

  • Davide Rossi

  • Maximilian Diehn

  • Ash A. Alizadeh

  • Andre Schultz

Medical Centers

  • Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, WA

  • Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA

  • Institute of Oncology Research, Bellinzona, SWITZERLAND

  • Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD

  • Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Foresight Diagnostics, Aurora, CO

  • Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA

  • Department of Medicine, Divisions of Hematology & Oncology, Stanford University Medical Center, Palo Alto, CA

  • MorphoSys AG, Planegg, Germany

Locations

  • United States

  • Germany

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • B cell lymphomas

  • Diffuse large B-cell lymphoma

Biomarkers

  • Peripheral blood mononuclear cell

  • DNA Damage Inducible Transcript 3

  • Circulating DNA

  • Plasma cell-free DNA

Drug/Treatment

  • ACP-196

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • Lenalidomide

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved